Integrated DNA Technologies Names Ajay Gannerkote as New President to Lead Bold Era of Innovation and Growth

Jan. 13, 2025

Experienced healthcare leader with more than 20 years of demonstrated success driving industry growth and transformation takes helm at global genomics company

CORALVILLE, Iowa & REDWOOD CITY, Calif.--(BUSINESS WIRE)--#CRISPR--Global genomics solutions leader Integrated DNA Technologies (IDT) has appointed Ajay Gannerkote as president, effective immediately. With a track record of driving growth and transformation across myriad sectors—including pharmaceuticals, medical devices, imaging, and healthcare providers—Gannerkote will lead IDT and continue advancing its mission of accelerating the pace of genomics.





“IDT has been at the center of revolutionizing genomic solutions, and Ajay’s well-rounded experience, strategic vision, and deep operational expertise will be a great asset to the company as it embarks on an exciting new chapter,” said Demaris Mills, Genomic Medicines Group Executive at Danaher. “I look forward to seeing Ajay apply his leadership skills to ensure IDT’s ongoing success and commitment to delivering innovative customized solutions for genomics pioneers.”

Gannerkote joins IDT from Siemens Healthineers where he led the ultrasound business as president. In this capacity, he led a global organization of more than 2,000 associates across more than 30 countries to achieve growth and profitability. Prior to this role, he was part of the healthcare operations team at a leading global private equity firm and served as a partner at McKinsey & Company, driving development of strategic growth strategies and orchestrating operations and commercial transformation of medical device and pharmaceutical clients.

“With the genomics industry at an inflection point, I’m excited about the opportunity to lead a company on the cutting edge of life-changing research and that in turn is advancing the future of medicine, the fight against cancer, and the race to cure many life-threatening diseases,” Gannerkote said. “IDT has built a stellar reputation as an innovative genomics company that works shoulder-to-shoulder with its customers to develop tailored scientific solutions. I’m honored to carry the company forward to its next stage of growth and enable its pioneering spirit to solve genomic scientists’ toughest challenges.”

Gannerkote earned an MBA with distinction from the Stephen M. Ross School of Business at the University of Michigan and a Bachelor of Science in Electronics and Telecommunication Engineering from the University of Mysore in India.

He succeeds Mills, who served as president of IDT for more than three years. In 2023, she was promoted to an elevated role as Genomic Medicines Group Executive at Danaher while continuing to serve as IDT’s president. IDT is a Danaher life sciences operating company.

About IDT

Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all.

IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health.

For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram.

Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use.


Contacts

Media Contact:


idtpr@idtdna.com
800-328-2661 (USA & Canada)


+1 319-626-8400 (outside USA)

Link
close
Search CRISPR Medicine